An Institutional Training Organization for First-Principles Biotech Investing and Company Building.

A student-run organization dedicated to rigorous, first-principles analysis of drug development, capital markets, and clinical outcomes — where biological reality meets investment conviction.

Explore Our Mission

Public Arm

Sector Teams (×5)
Investment Committee
Governance Board

Private Arm

4 Project Teams
PhD/Post-Doc Advisors
Cornell CTL Interface

Two Integrated Arms. One Mission.

Few undergraduate organizations operate across both public markets and venture formation. We do.

Cornell BioVentures operates two integrated arms: a student-managed public equities portfolio covering therapeutics across oncology, CNS, rare disease, genetic medicine, and immunology — and a venture studio that supports the commercialization of faculty-led biotech startups through scientific and commercial diligence.

We believe that extraordinary investment judgment in biopharma requires fluency across mechanistic biology, clinical trial design, regulatory science, and financial analysis simultaneously.

Why BioVentures

Biotech Investing is Not About Narratives. It is About Correctly Understanding Biology, Clinical Data, and Probability Before the Market Does.

"Biopharmaceutical investing sits at the intersection of mechanistic biology, clinical trial design, regulatory science, and financial analysis. Success requires fluency across all four, and the ability to synthesize them into a probability-weighted view, even when the data is incomplete."

Most finance training programs don't go here. Cornell BioVentures does. We train students to read primary literature, interpret endpoint design, evaluate therapeutic differentiation, and build investment theses where market expectations diverge from biological reality.

Sector Team Overview

Each team produces original investment theses grounded in primary literature and defends them before a formal investment committee.

Student sector teams cover five therapeutic areas. Members produce original investment theses and pitch to a formal Investment Committee using primary data, clinical trial analysis, and valuation frameworks. Members present live corporate presentations and defend theses to develop real investment judgment on public securities.

Oncology

Cancer Biology

Central Nervous System

Neurology · Psychiatry

Rare Disease

Orphan Therapeutics

Genetic Medicine

Gene & Cell Therapy

Immunology & Inflammation

Autoimmune · I&O

Our Board of Leadership

View Leadership Team

Josh Trogan (BSOC ‘28)

President

Jenny Chen (BSOC ‘28)

Executive VP of Investments

Arrth Mittal (BME ‘28)

Executive VP of Venture

Jon Manowitz (ILR‘28)

VP of Recruitment

Briana Mach (Dyson‘28)

VP of Operations

Zoe Chan (Dyson‘28)

VP of Marketing

Kritanu Saha (Econ & HBHS‘28)

VP of Finance

Board of Advisors

Meet the Advisors

Sriker Nadipuram

Founding Member, Critical Value Asset Management

Luc Ghaleb

Associate, Asset Development & Financing at RTW Investments

Dr. Jason Pitts

Principal, General Atlantic

Frank Truslow

Life Sciences Executive, Mid Atlantic Bio Angels

Michael King

MD & Senior Biotechnology Analyst, Rodman & Renshaw

How Members Are Trained

"Members present live corporate presentations and defend theses before the Investment Committee — developing real investment judgment on public securities."

DCF Modeling

RNPV

Peak Sales

Endpoint Analysis

Regulatory Strategy

Pipeline Diligence

KOL Networks

Catalyst Mapping

01.

Mechanistic Biology

Understanding the drug's mechanism before evaluating commercial potential. Primary literature review is non-negotiable.

02.

Clinical Trial Structure

Interpreting endpoint design (OS, PFS, ORR, HR), patient selection criteria, and readout probability with scientific rigor.

03.

Regulatory & Competitive Landscape

Situating assets within the standard of care, competitive pipeline dynamics, and regulatory pathway risk.

04.

Probability-Weighted Valuation

Assigning fair value under scientific and regulatory uncertainty using EV/Peak Sales and risk-adjusted NPV frameworks.

Latest News

Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.

June 5, 2026

Biotech Investing Organization & Venture Studio

Active Projects

4

Focus

Faculty-Led Biotech Startups

Institutional Partner

Cornell CTL

Advisory Structure

PhD / Post-Doc

Venture Studio for Faculty Biotech.

We partner with internal teams to evaluate, build, and scale biotech ventures through rigorous scientific and commercial analysis. Three project teams, each guided by PhD and Post-Doctoral advisors, interface directly with the Cornell Center for Technology Licensing (CTL).

Scientific diligence

Commercial landscape

IP assessment

Go-to-market strategy

4 Active Project Teams

Each team led by PhD/Post-Doc advisors with deep domain expertise in the relevant therapeutic or technology area.

Cornell CTL Interface

Direct engagement with Cornell's Center for Technology Licensing to support faculty-led IP commercialization pathways.

Scientific & Commercial Diligence

Teams produce both technical feasibility assessments and market opportunity analyses for early-stage biotech ventures.